Cargando…
Tocilizumab in severe COVID-19: A promise fulfilled
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Federation of Internal Medicine. Published by Elsevier B.V.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606258/ https://www.ncbi.nlm.nih.gov/pubmed/34836747 http://dx.doi.org/10.1016/j.ejim.2021.11.015 |
| _version_ | 1784602307131867136 |
|---|---|
| author | Levi, Marcel |
| author_facet | Levi, Marcel |
| author_sort | Levi, Marcel |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8606258 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | European Federation of Internal Medicine. Published by Elsevier B.V. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-86062582021-11-22 Tocilizumab in severe COVID-19: A promise fulfilled Levi, Marcel Eur J Intern Med Commentary European Federation of Internal Medicine. Published by Elsevier B.V. 2022-01 2021-11-22 /pmc/articles/PMC8606258/ /pubmed/34836747 http://dx.doi.org/10.1016/j.ejim.2021.11.015 Text en © 2021 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Commentary Levi, Marcel Tocilizumab in severe COVID-19: A promise fulfilled |
| title | Tocilizumab in severe COVID-19: A promise fulfilled |
| title_full | Tocilizumab in severe COVID-19: A promise fulfilled |
| title_fullStr | Tocilizumab in severe COVID-19: A promise fulfilled |
| title_full_unstemmed | Tocilizumab in severe COVID-19: A promise fulfilled |
| title_short | Tocilizumab in severe COVID-19: A promise fulfilled |
| title_sort | tocilizumab in severe covid-19: a promise fulfilled |
| topic | Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606258/ https://www.ncbi.nlm.nih.gov/pubmed/34836747 http://dx.doi.org/10.1016/j.ejim.2021.11.015 |
| work_keys_str_mv | AT levimarcel tocilizumabinseverecovid19apromisefulfilled |